Glenmark Pharmaceuticals LimitedNSE: GLENMARK

Press Release Feb 10 2025

· Issued by Glenmark Pharmaceuticals Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Winlevi® is the first topical acne treatment in nearly four decades, featuring a unique mechanism of action that targets androgen receptors without systemic effects. The filing includes a media release detailing the approval and its implications for patient care.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/press-release-feb-10-2025-11

Watch Glenmark Pharmaceuticals' latest callGlenmark Pharmaceuticals (NSE:GLENMARK) Q2 2026 Earnings Call · Replay · Nov 6

Glenmark Pharmaceuticals Limited on 6ix

Earlier from Glenmark Pharmaceuticals

Later from Glenmark Pharmaceuticals

All Glenmark Pharmaceuticals news releases